Incyte Announces Week 24 Results from TRuE-AD4 Phase III Trial of Opzelura LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results